ExodusPoint Capital Management’s Passage Bio PASG Stock Holding History

ExodusPoint Capital Management’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,330	Closed	-$169K	–	2556
2021 Q4	$169K	Sell	1,330 -90	-6%	-$14.7K	﹤0.01%	1861
2021 Q3	$283K	Buy	+1,420	New	+$339K	﹤0.01%	1638
2021 Q2	–	Sell	-698	Closed	-$244K	–	2685
2021 Q1	$244K	Buy	+698	New	+$298K	﹤0.01%	1782

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

ExodusPoint Capital Management's PASG Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 1,330 shares — an estimated $169K sold.

ExodusPoint Capital Management first reported a position in PASG in Q1 2021 and held it in 3 quarters. The position peaked at $283K in Q3 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

ExodusPoint Capital Management reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 1,330 Passage Bio shares in Q1 2022, an estimated $169K.
ExodusPoint Capital Management first reported a position in Passage Bio in Q1 2021 and held it in 3 quarters.
ExodusPoint Capital Management's Passage Bio position peaked at $283K in Q3 2021.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.